Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Results from the MAJIC-PV trial: ruxolitinib vs BAT for hydroxyurea resistant/intolerant PV

Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’s NHS Foundation Trust, London, UK, discusses results from the MAJIC-PV trial (ISRCTN61925716) of ruxolitinib vs best available therapy (BAT) for the treatment of hydroxyurea intolerant/resistant polycythemia vera (PV). Complete response (CR) and event-free survival (EFS) were significantly increased in the ruxolitinib group compared to the BAT group. A decrease in JAK2V617F allele fraction also correlated with increased EFS. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Geron: Membership on an entity’s Board of Directors or advisory committees; Keros: Consultancy; Constellation Pharmaceuticals, Inc., a MorphoSys Company: Membership on an entity’s Board of Directors or advisory committees, Research Funding; EHA: Other: Leadership role; MPN voice: Other: Leadership role; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Shire: Membership on an entity’s Board of Directors or advisory committees; Sierra: Honoraria; AOP Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Promedior: Membership on an entity’s Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Janssen: Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees; Galecto: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees, Other: Support for attending meetings, Research Funding; Galacteo: Membership on an entity’s Board of Directors or advisory committees; Celgene/BMS: Membership on an entity’s Board of Directors or advisory committees, Research Funding.